The European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire for patients with bone metastases: the EORTC QLQ-BM22.
OBJECTIVE
The aim of this study was to develop a bone metastases module to supplement the European Organisation for Research and Treatment of Cancer Core Questionnaire (EORTC QLQ-C30) or the EORTC QLQ-C15-PAL for patients with bone metastases.


METHODS
Phases 1-2 of module development were conducted in Canada, Australia and Germany according to EORTC QOL group guidelines. Phase 3 was conducted in nine countries in seven languages.


RESULTS
Sixty-one health-related quality of life (HRQOL) issues were generated from health care professionals (n=152) and patients (n=413). This resulted in a 22-item provisional module. Further testing in 170 patients from nine countries resulted in the EORTC QLQ-BM22 module, containing 22 items, conceptualised into both symptom scales, with five painful sites and three pain characteristics, and also functional scales, with eight functional interference and six psychosocial aspects.


CONCLUSIONS
This study provides a provisional comprehensive HRQOL measurement tool for future trials, which will continue to undergo further validation.
Chow
Edward
E
Sunnybrook Health Sciences Centre, 2075 Bayview Avenue, Toronto, Ontario, Canada M4N 3M5. Electronic address: edward.chow@sunnybrook.ca.
Hird
Amanda
A
Sunnybrook Health Sciences Centre, 2075 Bayview Avenue, Toronto, Ontario, Canada M4N 3M5.
Velikova
Galina
G
Cancer Research UK Clinical Centre, University of Leeds, St James's University Hospital, Leeds, UK.
Johnson
Colin
C
University Surgical Unit, Southampton General Hospital, UK.
Dewolf
Linda
L
European Organization for Research and Treatment of Cancer, Brussel, Belgium.
Bezjak
Andrea
A
Princess Margaret Hospital, University Health Network, University of Toronto, Toronto, Ontario, Canada.
Wu
Jackson
J
Tom Baker Cancer Centre, University of Calgary, Calgary, Alberta, Canada.
Shafiq
Jesmin
J
Liverpool Hospital, Liverpool, New South Wales, Australia.
Sezer
Orhan
O
Charité, Universitaetsmedizin Berlin, Germany.
Kardamakis
Dimitrios
D
University of Patras Medical School, Patras, Greece.
van der Linden
Yvette
Y
Radiotherapeutic Institute Friesland, Leeuwarden, The Netherlands.
Ma
Brigette
B
Prince of Wales Hospital, Chinese University of Hong Kong, Shatin, China.
Castro
Monica
M
Instituto de Oncologia Angel H. Roffo, Universidad de Buenos Aires, Argentina.
Arnalot
Palmira Foro
PF
Hospital de l'Esperança, Sant Josep de la Muntanya, Barcelona, Spain.
Ahmedzai
Sam
S
St Lukes Hospice, Little Common Lane, Sheffield, UK.
Clemons
Mark
M
Princess Margaret Hospital, University Health Network, University of Toronto, Toronto, Ontario, Canada.
Hoskin
Peter
P
Mount Vernon Hospital, Northwood, Middlesex, UK.
Yee
Albert
A
Sunnybrook Health Sciences Centre, 2075 Bayview Avenue, Toronto, Ontario, Canada M4N 3M5.
Brundage
Michael
M
Kingston Regional Cancer Centre, Kingston, Ontario, Canada.
Bottomley
Andrew
A
European Organization for Research and Treatment of Cancer, Brussel, Belgium.
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D001859:Bone Neoplasms / Q000523:psychology* / Q000556:secondary*; D005060:Europe; D005260:Female; D017408:Guidelines as Topic; D006305:Health Status Indicators; D006801:Humans; D007407:Interviews as Topic; D008297:Male; D008875:Middle Aged; D009369:Neoplasms / Q000523:psychology; D010358:Patient Participation; D011594:Psychometrics; D011788:Quality of Life; D011795:Surveys and Questionnaires / Q000592:standards